Siga Technologies Receives $9 Million Contract from U.S. Defense Department
By Connor Hart
Siga Technologies was awarded a $9 million contract by the U.S. Department of Defense for its flagship medicine used to treat smallpox.
The New York pharmaceutical company said Wednesday that the contract consists mostly of oral TPOXX, with a small amount of intravenous TPOXX. The contract marks the company's third procurement in the past three years.
Including this contract, Siga currently has approximately $154 million of outstanding oral and IV TPOXX orders, of which more than 85% were generated within the past three months.
TPOXX is an antiviral medicine approved in the U.S. and Canada to treat smallpox. The medicine is authorized in Europe and the U.K. for the treatment of smallpox, monkeypox, cowpox and vaccinia complications.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 21, 2024 16:31 ET (20:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States